AMGN Amgen Inc

Price (delayed)

$245.37

Market cap

$131.08B

P/E Ratio

24.1

Dividend/share

$7.4

EPS

$10.18

Enterprise value

$161.4B

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980. ...

Highlights
The revenue has grown by 4.6% year-on-year
The gross profit has increased by 4% year-on-year
The P/E is 7% below the 5-year quarterly average of 25.9 but 4.8% above the last 4 quarters average of 23.0
Amgen's equity has plunged by 90% YoY and by 86% from the previous quarter
AMGN's quick ratio is down by 22% year-on-year and by 15% since the previous quarter

Key stats

What are the main financial stats of AMGN
Market
Shares outstanding
534.2M
Market cap
$131.08B
Enterprise value
$161.4B
Valuations
Price to earnings (P/E)
24.1
Price to book (P/B)
149.21
Price to sales (P/S)
5.11
EV/EBIT
20.89
EV/EBITDA
14.51
EV/Sales
6.13
Earnings
Revenue
$26.32B
EBIT
$7.73B
EBITDA
$11.12B
Free cash flow
$8.42B
Per share
EPS
$10.18
Free cash flow per share
$15.36
Book value per share
$1.64
Revenue per share
$48.02
TBVPS
$54.26
Balance sheet
Total assets
$59.2B
Total liabilities
$58.28B
Debt
$36.85B
Equity
$916M
Working capital
$5.63B
Liquidity
Debt to equity
40.23
Current ratio
1.44
Quick ratio
0.9
Net debt/EBITDA
2.73
Margins
EBITDA margin
42.3%
Gross margin
75.2%
Net margin
21.7%
Operating margin
30.4%
Efficiency
Return on assets
9.3%
Return on equity
95.1%
Return on invested capital
17.2%
Return on capital employed
16.7%
Return on sales
29.4%
Dividend
Dividend yield
3.02%
DPS
$7.4
Payout ratio
72.7%

AMGN stock price

How has the Amgen stock price performed over time
Intraday
0.94%
1 week
4.54%
1 month
-2.59%
1 year
1.83%
YTD
9.07%
QTD
1.47%

Financial performance

How have Amgen's revenue and profit performed over time
Revenue
$26.32B
Gross profit
$19.79B
Operating income
$8.01B
Net income
$5.72B
Gross margin
75.2%
Net margin
21.7%
The net margin has declined by 23% year-on-year and by 4.4% since the previous quarter
The net income has contracted by 19% YoY and by 2.9% from the previous quarter
The company's operating margin fell by 14% YoY but it rose by 3.4% QoQ
AMGN's operating income is down by 10% year-on-year but it is up by 4.9% since the previous quarter

Growth

What is Amgen's growth rate over time

Valuation

What is Amgen stock price valuation
P/E
24.1
P/B
149.21
P/S
5.11
EV/EBIT
20.89
EV/EBITDA
14.51
EV/Sales
6.13
AMGN's EPS is down by 16% year-on-year
The P/E is 7% below the 5-year quarterly average of 25.9 but 4.8% above the last 4 quarters average of 23.0
Amgen's equity has plunged by 90% YoY and by 86% from the previous quarter
The P/S is 5% less than the 5-year quarterly average of 5.4 but 2.2% more than the last 4 quarters average of 5.0
The revenue has grown by 4.6% year-on-year

Efficiency

How efficient is Amgen business performance
The ROE has grown by 35% YoY and by 31% from the previous quarter
AMGN's return on sales is down by 19% year-on-year and by 3.3% since the previous quarter
AMGN's return on assets is down by 16% year-on-year and by 2.1% since the previous quarter
The ROIC has contracted by 12% YoY and by 3.4% from the previous quarter

Dividends

What is AMGN's dividend history
DPS
$7.4
Dividend yield
3.02%
Payout ratio
72.7%
Recent dividends

Financial health

How did Amgen financials performed over time
AMGN's quick ratio is down by 22% year-on-year and by 15% since the previous quarter
Amgen's current ratio has decreased by 13% YoY and by 9% from the previous quarter
Amgen's equity has plunged by 90% YoY and by 86% from the previous quarter
The debt rose by 13% year-on-year and by 11% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.